1. Home
  2. ANSC vs SVRA Comparison

ANSC vs SVRA Comparison

Compare ANSC & SVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANSC
  • SVRA
  • Stock Information
  • Founded
  • ANSC 2021
  • SVRA 2007
  • Country
  • ANSC United States
  • SVRA United States
  • Employees
  • ANSC N/A
  • SVRA N/A
  • Industry
  • ANSC
  • SVRA Biotechnology: Pharmaceutical Preparations
  • Sector
  • ANSC
  • SVRA Health Care
  • Exchange
  • ANSC Nasdaq
  • SVRA Nasdaq
  • Market Cap
  • ANSC 466.6M
  • SVRA 527.2M
  • IPO Year
  • ANSC 2023
  • SVRA N/A
  • Fundamental
  • Price
  • ANSC $10.94
  • SVRA $3.60
  • Analyst Decision
  • ANSC
  • SVRA Buy
  • Analyst Count
  • ANSC 0
  • SVRA 8
  • Target Price
  • ANSC N/A
  • SVRA $6.63
  • AVG Volume (30 Days)
  • ANSC 11.5K
  • SVRA 1.7M
  • Earning Date
  • ANSC 01-01-0001
  • SVRA 11-11-2025
  • Dividend Yield
  • ANSC N/A
  • SVRA N/A
  • EPS Growth
  • ANSC N/A
  • SVRA N/A
  • EPS
  • ANSC 0.14
  • SVRA N/A
  • Revenue
  • ANSC N/A
  • SVRA N/A
  • Revenue This Year
  • ANSC N/A
  • SVRA N/A
  • Revenue Next Year
  • ANSC N/A
  • SVRA N/A
  • P/E Ratio
  • ANSC $80.37
  • SVRA N/A
  • Revenue Growth
  • ANSC N/A
  • SVRA N/A
  • 52 Week Low
  • ANSC $10.32
  • SVRA $1.89
  • 52 Week High
  • ANSC $10.94
  • SVRA $4.70
  • Technical
  • Relative Strength Index (RSI)
  • ANSC 64.39
  • SVRA 64.24
  • Support Level
  • ANSC $10.91
  • SVRA $3.47
  • Resistance Level
  • ANSC $10.94
  • SVRA $3.72
  • Average True Range (ATR)
  • ANSC 0.01
  • SVRA 0.18
  • MACD
  • ANSC 0.00
  • SVRA -0.03
  • Stochastic Oscillator
  • ANSC 100.00
  • SVRA 52.80

About ANSC Agriculture & Natural Solutions Acquisition Corporation

Agriculture & Natural Solutions Acquisition Corp is a blank check company.

About SVRA Savara Inc.

Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.

Share on Social Networks: